Meiji Seika Pharma
4919.TTokyo, Japan· Est.
Japanese pharmaceutical company developing innovative anti-infectives and oncology drugs through small molecule discovery platforms.
Is this your company? Claim your profile to update info and connect with investors.
Claim profileAI Company Overview
Japanese pharmaceutical company developing innovative anti-infectives and oncology drugs through small molecule discovery platforms.
Infectious DiseaseOncology
Technology Platform
Small molecule drug discovery platform with specialized expertise in anti-infective development, particularly antibiotics and antifungal agents targeting resistant pathogens.
Opportunities
Growing global focus on antimicrobial resistance creates opportunities for novel antibiotics, while expansion into oncology offers diversification beyond anti-infectives.
Risk Factors
Antibiotic development faces economic challenges due to pricing pressures and stewardship requirements, while oncology competition is intense from larger pharmaceutical companies.
Competitive Landscape
Competes with large pharma companies like Merck and Pfizer in anti-infectives, and numerous oncology-focused biotechs; differentiated by specialized antibiotic expertise in an area many have exited.